Ocugen has advanced three gene therapies with multiple phase II/III readouts and filings lined up for 2026, with the stock surging 75% year-to-date. As a pioneering biotechnology leader in gene therapies for blindness diseases, Ocugen's modifier gene therapy platform uses a gene-agnostic approach that addresses entire diseases caused by imbalances in multiple gene networks.
Cyborg Score Rationale
Ocugen has completed enrollment for its Phase 3 liMeliGhT trial for OCU400 with positive 3-year Phase 1/2 data, and remains on track to file a rolling BLA in Q3 2026. The company is approaching multiple clinical and regulatory catalysts, though cash runway constraints require ongoing financing to sustain operations into 2027.
Top Insights
OCU400 has shown potential to treat multiple gene mutations associated with retinitis pigmentosa with a one-time subretinal injection.
As of September 30, 2025, Ocugen had $32.9 million in cash and equivalents, down from $58.8 million at year-end 2024, requiring ongoing capital raises.
OCU410ST (Stargardt disease) interim data expected mid-2026, with BLA filing planned for H1 2027.
liMeliGhT represents the first and largest gene therapy registrational trial for broad RP patients, using a gene-agnostic study approach addressing multiple genetic mutations and disease pathways.
Named Competitors
Anti-complement therapies — Multiple-injection treatments for geographic atrophy targeting complement pathway only